

# COMBINE –

## OPEN CALL for preclinical and clinical data sets

COMBINE is an IMI2 consortium, which supports the work of the IMI AMR Accelerator by identifying better ways to translate preclinical know-how into clinical practice and vice-versa. COMBINE will perform systematic cross-study analyses of relevant data sets originating from the AMR community, with the goal of improving the success of R&D efforts across the AMR community.

The COMBINE consortium is launching its first **OPEN CALL FOR DATA** to find partners worldwide that are willing to share data from **studies of prevention or treatment of bacterial infections**. The extended analyses we can perform using your data will help the AMR community to learn from the body of available science. **YOU** can help to prevent future failures and increase success rates of future developments by giving COMBINE access to data.

### What are WE looking for?

Data from the study of medicines or candidate medicines for prevention or treatment of bacterial infections, e.g. **antibiotics, vaccines, monoclonal antibodies, pathoblockers and phages**.

We are specifically looking for

- 1.) Matched pairs of preclinical and clinical data (toxicology, PK/PD, efficacy)
- 2.) Data from clinical trials for prevention or treatment of bacterial infections

Data from **all relevant trials, both success and failures, are highly relevant** to derive the desired learnings.

[www.amr-accelerator.eu](http://www.amr-accelerator.eu)

### What pathogens are WE interested in?

ESCAPE pathogens such as ESBL positive *Escherichia coli* and *Clostridioides difficile*, as well as *Neisseria gonorrhoeae* and *Mycobacterium tuberculosis*.

### Are YOU interested?

Please send an e-mail to **AMR-data-technical.COMBINE@grit42.com** to submit your **Expression of Interest** or ask technical questions; or at **AMRCOMBINEscientific@pei.de** to understand what type of analysis we could perform with your data sets

#### IMI AMR ACCELERATOR PARTNERS:

ASCLEPIA | BEAM ALLIANCE | BILL & MELINDA GATES FOUNDATION | BIOASTER | BIOCOM | BIOVERSYS | C-PATH | CHU DE POITIERS | CONSIGLIO NAZIONALE DELLE RICERCHE | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE | ERASMUS MC UNIVERSITY | EVOTEC | FFUND | FORSCHUNGSZENTRUM BORSTEL | FOUNDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS | FRAUNHOFER GESELLSCHAFT | GRITSYSTEMS AS | GSK | HELMHOLTZ CENTRE FOR INFECTION RESEARCH | HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND | HOPITEAUX DE TOURS | IDMIT | IMABIOTECH | INSERM | INSTITUTE PASTEUR PARIS | INSTITUTE PASTEUR DE LILLE FOUNDATION | JANSSEN | LATVIA INSTITUTE OF ORGANIC SYNTHESIS | LEIDS UNIVERSITAIR MEDISCH CENTRUM | LYGATURE | MEDICAL UNIVERSITY OF VIENNA | MITOLOGICS | NHS | NICE | NOSOPHARM | PAUL-EHRlich-INSTITUT | PUBLIC HEALTH ENGLAND | QPS NETHERLANDS | SCIENSANO | SERMAS | SKANE HOSPITAL LUND | STATENS SERUM INSTITUT | SYNAPSE | TB ALLIANCE | UNIVERSITE DE POITIERS | UNIVERSITE PARIS SORBONNE | UNIVERSITEIT LEIDEN | UNIVERSITET ANTWERPEN | UNIVERSITY CARLOS III MADRID | UNIVERSITY OF COPENHAGEN | UNIVERSITY OF DUNDEE | UNIVERSITY OF KÖLN | UNIVERSITY OF LIVERPOOL | UNIVERSITY OF PADOVA | UNIVERSITY OF PAVIA | UNIVERSITY OF ZARAGOZA | UPPSALA UNIVERSITET